NASDAQ: JAZZ

Jazz Pharmaceuticals (JAZZ) Stock Analysis & Forecast

Nov 13 close

$241.55+1.18 (+0.5%)

Gekko Brief

Nov 9 close

Jazz Pharmaceuticals closed at $243.55 on 9 November 2026, +3.7% on the day. The price sits above both the 50-day ($229.37) and 200-day ($218.47) moving averages, inside a 52-week range of $128.80 to $266.38. The GekkoIndex reads 49.9, in the Neutral zone, down 12.2 points over five sessions. Gekko Fair Value is $324.61, so the price is 25% below it.

The next earnings report is due on 23 February 2027, 100 days away (after close). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 8.1% across the report. Over the last 30 days there was 1 unusual options signal. Seasonally, the next 20 trading days from this point averaged +5.2% over the last 5 years, rising in 3 of them.

17 firms rate the stock: 16 buy, 1 hold and 0 sell, with a consensus target of $295.50. A typical daily move is about 3.2%, and a typical 20-day move about 4.8%. On the swing-trade checklist, 5 items read supportive and 0 read as a headwind.

A plain summary of the figures as of the Nov 9, 2026 close.

Jazz Pharmaceuticals price vs fair value

$310.39$241.55Nov ’25May ’26Nov ’26
Close $241.55200-day averageGekko Fair Value $310.39

Jazz Pharmaceuticals quick facts

Market cap
$15.50B
P/E ratio
71.1
Forward P/E
10.6
EPS, TTM
$3.38
Revenue, TTM
$4.72B
Profit margin
4.4%
Dividend yield
—
Beta
0.37
Volume
496,700 avg 799,729
1-year return
+76.7%
Typical daily move
±3.3%
Typical 20-day move
±4.9%
50-day average
$229.13
200-day average
$220.03
Next earnings
Feb 23 after close
Shares outstanding
64.19M
52-week range
$136.56$266.38

Jazz Pharmaceuticals swing-trade checklist

Jazz Pharmaceuticals scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

5 supportive1 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $241.55 is above the 50-day ($229.13) and 200-day ($220.03) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    51.5, Neutral

    Reading 51.5 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    22.2% below

    Price is 22.2% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +1.4% on average

    From this point in the calendar, the next 20 trading days averaged +1.4% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Jazz Pharmaceuticals stock chart and price history

Jazz Pharmaceuticals closed at $241.55 on Nov 13, 2026, +76.7% over the past year, inside a 52-week range of $136.56 to $266.38.

Close50-day average200-day averageVolume
Jazz Pharmaceuticals share price, past year, with 50-day and 200-day moving averages and volume$150$200DecJan 2026FebMarAprMayJunJulAugSepOctNov241.55

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+12.7%
3 months
−2.7%
6 months
+5.6%
1 year
+76.7%
The full JAZZ chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open JAZZ in Gekko

Follow Jazz Pharmaceuticals through every session

Put JAZZ on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track JAZZ in GekkoFree for 7 days. No credit card required.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals researches, develops, and brings to market medicines sold across the United States, Europe, and other international regions. Its treatments address conditions such as narcolepsy and idiopathic hypersomnia, seizure disorders including Lennox-Gastaut and Dravet syndromes, several forms of leukemia and lymphoma, certain lung and biliary tract cancers, a specific type of glioma, and severe veno-occlusive disease, with products including Xywav, Epidiolex, Rylaze, Enrylaze, Zepzelca, Ziihera, Modeyso, Defitelio, and Vyxeos.

Beyond its marketed products, the company runs a pipeline of experimental treatments at various clinical stages, spanning cancers such as gastroesophageal adenocarcinoma, biliary tract cancer, breast cancer, acute myeloid leukemia, and rare tumor types, along with therapies aimed at glioma and absence epilepsy. It advances some of this work through licensing and collaboration arrangements with other firms, including Redx Pharma, Autifony Therapeutics, Zymeworks, Sumitomo Pharma, and Werewolf Therapeutics.

Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland. Its shares are listed on the NASDAQ under the ticker JAZZ.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
jazzpharma.com

Jazz Pharmaceuticals GekkoIndex: the smart money zone

Jazz Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.5, in the Neutral zone, down 1.4 points over five sessions.

010051.5Neutral

Down 1.4 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying33+0.4%+2.4%+2.6%+3.3%
Accumulation160+1.2%+1.1%+0.8%+4.0%
Neutral (current zone)464+0.6%+1.3%+2.7%+7.4%
Distribution39−1.7%−2.2%−1.1%−5.7%
Selling6Too few readings yet

Average JAZZ share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the JAZZ price, zone by zone.Track JAZZ in Gekko

Is Jazz Pharmaceuticals stock overvalued? Gekko Fair Value

Jazz Pharmaceuticals trades 22.2% below Gekko Fair Value of $310.39, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Jazz Pharmaceuticals shares are worth, recalculated every trading day.

$310.39

Gekko Fair Value, Nov 14, 2026

22.2% Undervalued

At the end of Aug 2026 the price was 23.1% below the estimate.

Gekko Fair ValueShare price, month end
$310$242Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open JAZZ in Gekko

Jazz Pharmaceuticals insider and Congress trading

No open-market insider purchases were filed for Jazz Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for JAZZ in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every JAZZ insider filing, plotted on the chart in Gekko.Open JAZZ in Gekko

Congress trades last 90 days

No trades in JAZZ were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for JAZZ, plotted on the chart in Gekko.Open JAZZ in Gekko

Buybacks

Jazz Pharmaceuticals has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$225.0M
As a share of market cap
1.45%

From company filings.

Unusual options activity last 30 days

1signal, 100% of the flagged premium in calls.

Latest: Bullish flow on Nov 4, $338K in unusual premium.

Hedge funds and billionaires quarter ended Sep 30

1of the funds Gekko tracks holds JAZZ.

0added0opened1trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Jazz Pharmaceuticals earnings: next date and track record

Jazz Pharmaceuticals reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±8.1%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+5.5%Feb ’25−14.2%May ’25−8.8%Aug ’25−2.7%Nov ’25+13.6%Feb ’26+9.9%May ’26+3.5%Aug ’26+6.4%Nov ’26

Last earnings call, Nov 2, 2026 AI summary

What they said
Jazz Pharmaceuticals reported record Q3 2026 revenues of $1.24 billion, up 10% year-over-year. Oncology revenues surged 35% YoY driven by Modeyso and Zepzelca launches plus sustained Xywav demand. FDA approval and launch of Ziihera in first-line HER2-positive metastatic GEA marked a key milestone, with peak sales potential of $3-5 billion. Jazz also acquired Actio Biosciences, adding pipeline asset ABS-1230 for rare epilepsy.
Guidance
Management raised 2026 full-year revenue guidance following strong Q3 performance. Specific updated targets to be detailed by CFO Phil Johnson. Ziihera launch momentum and diversified portfolio growth underpin management's positive outlook.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 2, 2026−$3.88
est −$4.03
+3.7%$1.24B
est $1.21B
+2.9%+6.4%
Aug 3, 2026$4.89
est $5.06
−3.4%$1.21B
est $1.11B
+8.4%+3.5%
May 5, 2026$6.34
est $4.66
+36.1%$1.20B
est $1.17B
+2.8%+9.9%
Feb 24, 2026$6.64
est $6.51
+2.1%——+13.6%
Nov 5, 2025$8.13
est $5.95
+36.6%$1.13B
est $1.11B
+1.3%−2.7%
Aug 5, 2025−$8.25
est −$6.12
−34.8%$1.05B
est $1.05B
−0.1%−8.8%
May 6, 2025$1.68
est $4.66
−63.9%$897.8M
est $1.06B
−15.7%−14.2%
Feb 25, 2025$6.60
est $5.81
+13.6%$1.09B
est $985.0M
+10.5%+5.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Jazz Pharmaceuticals stock forecast and analyst price targets

Analysts’ average 12-month price target for Jazz Pharmaceuticals is $296.77, +22.9% from the last close, from 17 firms rating the stock in the last 90 days.

$296.77consensus 12-month target, +22.9% from the last close
Low $229High $337
Buy16
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 17 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Morgan StanleyBuy, maintained$324+34.1%
Nov 12Piper SandlerBuy, reiterated$330+36.6%
Nov 3BarclaysBuy, maintained$275+13.8%
Nov 3RBC CapitalBuy, maintained$305+26.3%
Nov 3Wells FargoBuy, reiterated$300+24.2%
+2.7%average 20-day move after past Neutral readings
+1.4%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Jazz Pharmaceuticals seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Jazz Pharmaceuticals averaged +1.4% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−13.2%2021+2.6%2022+0.5%2023−1.0%2024+20.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+1.4%2 of 5
Next 10 trading days+0.1%2 of 5
Next 15 trading days+0.7%2 of 5
Next 20 trading days+1.4%3 of 5
Next 30 trading days+3.6%2 of 5

For scale, JAZZ’s typical 20-trading-day move in either direction is about 4.9%.

Jazz Pharmaceuticals market cap and key statistics

Jazz Pharmaceuticals’s market cap is $15.50B, with a P/E ratio of 71.1 and revenue of $4.72B over the last twelve months.

Valuation

Market cap
$15.50B
P/E ratio
71.1
Forward P/E
10.6
EPS, TTM
$3.38
Gekko Fair Value
$310.39

Trading

Volume
496,700
Avg volume, 20 days
799,729
52-week high
$266.38
52-week low
$136.56
Shares outstanding
64.19M

Financials

Revenue, TTM
$4.72B
Profit margin
4.4%
Return on equity
5.1%
Quarterly earnings growth, YoY
+3.2%

Risk and income

Beta
0.37
Typical daily move
±3.3%
Typical 20-day move
±4.9%

Jazz Pharmaceuticals stock news this week

Coverage of Jazz Pharmaceuticals this week reads neutral: 3 positive, 4 neutral and 1 negative headlines.

News sentiment neutral

Jazz Pharmaceuticals peers

Jazz Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Jazz Pharmaceuticals stock FAQ

What is Jazz Pharmaceuticals’s market cap?

Jazz Pharmaceuticals’s market cap is $15.50B at the Nov 13, 2026 close of $241.55, with 64.19M shares outstanding. The shares trade on a P/E ratio of 71.1.

What is the Jazz Pharmaceuticals stock forecast?

The consensus analyst 12-month price target for Jazz Pharmaceuticals is $296.77, +22.9% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Jazz Pharmaceuticals stock overvalued or undervalued?

On Gekko’s estimate Jazz Pharmaceuticals is undervalued: the Nov 13, 2026 close of $241.55 is 22.2% below Gekko Fair Value of $310.39. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Jazz Pharmaceuticals report earnings next?

Jazz Pharmaceuticals is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of $6.97 per share on revenue of $1.28B. Jazz Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 8.1% on average across the report.

What is Jazz Pharmaceuticals’s 52-week high and low?

Jazz Pharmaceuticals’s 52-week high is $266.38 and its 52-week low is $136.56; it closed at $241.55 on Nov 13, 2026, +76.7% over the past year.

Is Jazz Pharmaceuticals stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, fair value, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Jazz Pharmaceuticals?

Gekko flagged 1 unusual options signal in Jazz Pharmaceuticals over the last 30 days, with $338K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 4, 2026 with $338K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Jazz Pharmaceuticals the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.